Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 14/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086253 | 0.91 | TNK2 (0.50) | IGF1RTNK2 | |
| SCHEMBL5086140 | 0.88 | TNK2 (0.45) | IGF1RTNK2 | |
| SCHEMBL5081252 | 0.88 | TNK2 (0.42) | IGF1RTNK2 | |
| SCHEMBL5081320 | 0.86 | TNK2 (0.44) | IGF1RTNK2CYP3A4 | |
| SCHEMBL5080636 | 0.84 | IGF1R (0.48) | IGF1RTNK2CYP3A4 | |
| SCHEMBL3040790 | 0.82 | IGF1R (0.51) | IGF1RTNK2CYP3A4NPC1RAB9A | |
| SCHEMBL5079162 | 0.81 | IGF1R (0.50) | IGF1RTNK2CYP3A4NPC1RAB9A | |
| SCHEMBL4073244 | 0.80 | IGF1R (0.51) | IGF1RTNK2CYP3A4 | |
| SCHEMBL400088 | 0.77 | TNK2 (0.77) | IGF1RTNK2CYP3A4 | |
| SCHEMBL5083298 | 0.76 | IGF1R (0.40) | IGF1RTNK2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979002-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008076143-A1 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007075554-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |